Literature DB >> 18210299

Does the introduction of sentinel node biopsy increase the number of node positive patients with early breast cancer? A population based study form the Danish Breast Cancer Cooperative Group.

Anders Husted Madsen1, Anni Ravnsbaek Jensen, Peer Christiansen, Jens Peter Garne, Soeren Cold, Marianne Ewertz, Jens Overgaard.   

Abstract

BACKGROUND: The validation series of sentinel lymph node biopsy (SLNB) in the treatment of breast cancer have shown that 10-20% more lymph node metastases are detected. However, their impact has never been studied in populations where the method has been fully implemented. In a population-based setting, the objective of the current study was to estimate the increased risk of metastases after introduction of the sentinel lymph node biopsy technique.
METHODS: We identified all new breast cancer patients in three different counties in two time periods (1996-1997 and 2002-2003). The study cohort was comprised of 2 932 patients. The main outcome was the frequency of patients with metastases. The frequencies of patients with metastases were compared as well as adjusted (using a multivariate logistic regression) and unadjusted odds-ratio for detecting lymph node metastases.
RESULTS: In counties where sentinel lymph node biopsy was implemented, the frequency of patients with lymph node metastases increased significantly 7.3% (95% CI: 1.0-13.7%) and 13.3% (95% CI: 7.3-19.3%), respectively. In the county without sentinel lymph node biopsy, an insignificant increase of 6.9% (-0.1-13.9%) in the frequency of patients with metastases was seen. The adjusted odds- ratio for detecting lymph node metastases was 1.41 (1.07-1.87) and 1.70 (1.30-2.23) in the counties with SLNB.
CONCLUSION: The frequency of patients with metastases increased significantly in counties where sentinel lymph node biopsy was implemented.

Entities:  

Mesh:

Year:  2008        PMID: 18210299     DOI: 10.1080/02841860701727436

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  4 in total

1.  Patterns of nodal staging during breast conservation surgery in the medicare patient: will the ACOSOG Z0011 trial change the pattern of care?

Authors:  Catherine E Loveland-Jones; Karen Ruth; Elin R Sigurdson; Brian L Egleston; Marcia Boraas; Richard J Bleicher
Journal:  Breast Cancer Res Treat       Date:  2014-01-19       Impact factor: 4.872

2.  Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme.

Authors:  Ondrej Majek; Jan Danes; Miroslava Skovajsova; Helena Bartonkova; Lucie Buresova; Daniel Klimes; Petr Brabec; Pavel Kozeny; Ladislav Dusek
Journal:  BMC Public Health       Date:  2011-05-10       Impact factor: 3.295

3.  Assessment of breast cancer opportunistic screening by clinical-pathological indicators: a population-based study.

Authors:  A Bordoni; N M Probst-Hensch; L Mazzucchelli; A Spitale
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

Review 4.  The sentinel node in breast cancer.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2008-10-04       Impact factor: 3.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.